Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and Pituitary ACTH Hypersecretion

cyc 202 has been researched along with Pituitary ACTH Hypersecretion in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Barkhoudarian, G; Ben-Shlomo, A; Carmichael, JD; Desai, M; Heaney, AP; Kelly, D; Liu, NA; Lu, L; Mamelak, AN; Melmed, S; Mirocha, J; Noureddin, M; Stolyarov, Y; Swerdloff, RS; Tighiouart, M; Wang, C; Yuen, K1
Tritos, NA1
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R1
Reincke, M; Theodoropoulou, M1
Araki, T; Ben-Shlomo, A; Cuevas-Ramos, D; Hong, J; Liu, NA; Melmed, S; Tone, M; Tone, Y1
Ben-Shlomo, A; Fan, XM; Jiang, H; Lin, S; Liu, NA; Melmed, S; Wawrowsky, K1

Reviews

2 review(s) available for cyc 202 and Pituitary ACTH Hypersecretion

ArticleYear
Advances in the medical treatment of Cushing's syndrome.
    The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4

    Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin

2019
Tumor-Directed Therapeutic Targets in Cushing Disease.
    The Journal of clinical endocrinology and metabolism, 2019, 03-01, Volume: 104, Issue:3

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin

2019

Other Studies

4 other study(ies) available for cyc 202 and Pituitary ACTH Hypersecretion

ArticleYear
Treatment of Cushing Disease With Pituitary-Targeting Seliciclib.
    The Journal of clinical endocrinology and metabolism, 2023, 02-15, Volume: 108, Issue:3

    Topics: Adrenocorticotropic Hormone; Adult; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Prospective Studies; Roscovitine

2023
New Hope for a Tumor-Directed Therapy for Cushing Disease.
    The Journal of clinical endocrinology and metabolism, 2023, 02-15, Volume: 108, Issue:3

    Topics: Humans; Neoplasms; Pituitary ACTH Hypersecretion; Pituitary Diseases; Pituitary Gland; Roscovitine

2023
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:7

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents; Cyclin E; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Primary Cell Culture; Pro-Opiomelanocortin; Purines; Roscovitine; Tumor Cells, Cultured; Young Adult

2015
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, May-17, Volume: 108, Issue:20

    Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Animals, Genetically Modified; Antineoplastic Agents; Corticosterone; Cyclin E; Cyclin-Dependent Kinases; Gene Expression Regulation; Mice; Pituitary ACTH Hypersecretion; Purines; Roscovitine; Zebrafish

2011